Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilazodone Long-term Safety in Pediatric MDD
NCT02436239Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- May 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of vilazodone in major depressive disorder (MDD), sponsored by Forest Laboratories. Started May 2015; status: completed.
02
Drugs
vilazodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02436239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436239.